Comparing the costs and benefits of the use of an mRNA HR-HPR assay to a DNA HR-HPV assay in the proposed cervical screening programme in France

Cervical cancer is the fourth most common cancer in women aged 15 to 44 years in France. With the implementation of cytology-based cervical screening, cervical cancer incidence and mortality have decreased over time, however, cervical cancer remains a concern. As cervical cancer is primarily caused by persistent infection with high-risk human papillomaviruses (HR-HPV), guidelines for Read More >
User experience and workflow performance: a pilot evaluation of the Genius Digital Diagnostics System for screening cervical cytology samples

It is generally understood that the cytology work process can be stressful and fatiguing affecting technicians’ performance and job satisfaction on a day-to-day basis and in the longer term. This study assessed the performance and user experience of cytotechnologists (CTs) reviewing liquid-based cytology samples using a new digital cytology platform Genius Digital Diagnostics System (Genius Read More >
Modelling the costs and benefits of an mRNA compared to a DNA high-risk HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada

Cases of cervical cancer in Canada have decreased recently as a result of cytology-based screening programs. However, cervical cancer remains a relatively common and preventable cause of cancer in women. As cervical cancer is primarily caused by persistent genital infection with high-risk (HR) human papillomaviruses, Ontario Health has been evaluating implementing HPV-based testing in cervical Read More >
Research in Dravet syndrome and cervical cancer screening presented at international conferences

Aquarius has recently presented posters at international conferences (ISPOR, a conference for the leading professional society for health economics and outcomes research and EUROGIN, an international multidisciplinary HPV conference), exploring the impact of improving healthcare for two very different conditions: Dravet syndrome (rare debilitating epilepsy) and cervical cancer.
Using an mRNA versus DNA test in the English cervical screening programme can save £15m annually and reduce unnecessary testing

The results of our economic evaluation comparing the use of mRNA and DNA assays in screening for cervical cancer in England were published in BMJ Open and are now available online. Results show large cost savings from avoiding unnecessary testing and follow-up, which can benefit women and healthcare services.
Improving patient care with rapid point of care tests

Dr Elisabeth Adams, Managing Director of Aquarius Population Health, presented on opportunities for rapid tests in influenza and HPV at international conferences in June. This has been a busy week for the Aquarius Population Health team. We had two posters at the Society for Medical Decision Making in London (12-15th June), which Elisabeth presented. The Read More >
Rapid on-demand testing of HPV and cervical cancer prevention: IPV Conference in Lisbon

Aquarius Population Health will be presenting European screening programmes outcomes and opportunities for rapid HPV testing in the UK at the 2015 HPV conference in Lisbon. http://www.hpv2015.org